We next examined the molecular and functional response to single and combined BRAF/MEK inhibition in a panel of 6 LCSC lines (LCSC1, LCSC2, LCSC3, LCSC4, LCSC5, LCSC6) derived from patients with NSCLC of different histological origin (large-cell neuroendocrine carcinoma: LCSC1; squamous cell carcinoma: LCSC2, LCSC3 and LCSC4; adenocarcinoma: LCSC5, LCSC6). Here, BRAF is linked to adenocarcinoma.